Men must agree to use adequate contraception prior to enrollment, for the duration of study participation and for at least  months thereafter
Women of child-bearing potential and men of childbearing potential must agree to use adequate contraception starting with the first dose of study therapy, for the duration of study participation, and for an additional  days after the last dose of study medication; note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject\r\n* Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the treating physician and principal investigator should be informed immediately\r\n* While on the study, women should not breast-feed\r\n* Subjects of childbearing potential are defined as those who have not been surgically sterilized and/or have had a menstrual period in the past year
Women of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study; both men and women must agree to use a barrier method of contraception for the duration of the study and until  weeks after the final dose
Women of childbearing potential (defined as women under the age of  with intact ovaries and uterus) must agree to use adequate contraception prior to study entry and for the duration of study participation; they must also have a negative urine pregnancy test within  days of starting treatment
Women of childbearing potential and men should remain abstinent or agree to use an effective form of contraception and to continue its use for the duration of study treatment and for a period of time after the last dose of study treatment
Pregnancy or lactation; women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation
Men must agree to use adequate contraception prior to study entry, for the duration of study participation and for at least  months after last radium  dose
Women of childbearing potential must have a negative pregnancy test at screening and must agree to use adequate contraception prior to study entry, for the duration of study participation, and for  months after the last dose of IMGN and gemcitabine
Women of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study; both men and women must agree to use a barrier method of contraception for the duration of the study and until  weeks after the final dose of UC- (expected to be greater than  half-lives from pre-clinical data)
Men and women of childbearing potential must agree to use adequate contraception from the time of consent through  months after final nivolumab study treatment
Because the effects of zydelig on the developing human fetus are unknown, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Female subjects of childbearing potential should have a negative pregnancy test within  hours prior to receiving the first dose of zydelig. Male subjects must agree to use an adequate method of contraception starting with the first dose of the study drug Zydelig. Female and male participants must agree to use contraception for at least  days after the last dose of Zydelig. Women of childbearing potential is defined as women who continues to have menstrual periods, have not had a tubal ligation, or the removal of fallopian tubes, ovaries or uterus.
Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation
Men must agree to use adequate contraception prior to study entry, for the duration of study participation and for at least  months thereafter
Men treated or enrolled on this protocol must agree to use adequate contraception prior to the first dose of study therapy, for the duration of the study participation, and for  days after the last dose of study therapy
Women of childbearing potential and men must agree to use adequate contraception
The subject must agree to use two effective forms of contraception beginning at least four () weeks prior to study entry, and continuing to do so for the duration of their participation in the study
DONOR: Women of childbearing potential and men must agree to use adequate contraception with two different forms, including one barrier method, during participation in the study and for  weeks following dosing with BL-; abstinence is acceptable if this is the established and preferred contraception for the subject
Women of childbearing potential and men must agree to use adequate contraception (simultaneous use of  methods of birth control) prior to study entry, for the duration of study participation and for  days following completion of therapy.
Women participate in the study must be surgically sterile, post-menopausal, or women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation and after for a certain amount of time\r\n* The individual methods of contraception and duration should be determined in consultation with the investigator; the duration of mandatory contraception is based on clearance of the investigational drug ( half-lives after treatment completion); for women, an additional  days is required to complete an ovulatory cycle; calculation of duration of mandatory contraception: the half-life of cisplatin is - minutes, half-life of methotrexate is - hours and half-life of gemcitabine is - minutes; thus, contraception is required for up to  weeks after the last treatment for women of child-bearing potential\r\n* Women must have a negative serum or urine pregnancy test within  hours prior to the start of transarterial chemoperfusion treatment\r\n* Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Men participate in the study must be surgically sterile or must agree to use adequate contraception prior to study entry and for the duration of study participation and after for a certain amount of time (as defined below); the investigator shall review contraception methods and the time period that contraception must be followed; the duration of mandatory contraception is based on clearance of the investigational drug ( half-lives after treatment completion); for males, an additional  days is required to complete turnover of drug-exposed sperm; calculation of duration of mandatory contraception: the half-life of cisplatin is - minutes, half-life of methotrexate is - hours and half-life of gemcitabine is - minutes; thus, contraception for men is required for up to  weeks after the last treatment
Women of childbearing potential and men should agree to use adequate contraception prior to study entry and for the duration of study participation and women who are breast feeding are excluded from the study; both women and men should be fully informed of the lack of reproductive toxicity testing, and women must have a negative pregnancy test prior to enrollment
Women of childbearing potential and all men must agree to use an approved form of contraception (e.g. oral, transdermal patch, implanted contraceptives, intrauterine device, diaphragm, condom, abstinence or surgical sterility) prior to study entry and for the duration of study participation through  days after the last dose of the last treatment drug. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for  days following completion of therapy
Men and women of childbearing potential who do not practice contraception; women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation
Women of child bearing potential must have a negative pregnancy test (blood or urine) within  days before treatment and agree to use appropriate contraception from study screen through the duration of the trial; men must agree to use appropriate contraception from study screen through the duration of the trial
Women of child bearing potential must have a negative pregnancy test (blood or urine) within  days before treatment and agree to use appropriate contraception from study screen through the duration of the trial; men must agree to use appropriate contraception from study screen through the duration of the trial
Men and women of childbearing potential who do not practice contraception; women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation
Women of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care
Pregnant or lactating women; women of childbearing potential must use effective contraception methods prior to study entry, for the duration of study participation, and for  months after the last dose of MCLA-.
Female patients of childbearing potential must have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least  months after discontinuation of study drug.
Women of childbearing potential must agree to use two reliable methods of contraception from screening and up to  days after discontinuation of study treatment
Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the  days period after last study drug dosing. The investigator should advise the patient how to achieve an adequate contraception.
Teratogenic effects of cenersen are unknown, women of child-bearing potential & men must agree to use adequate contraception prior to study entry & for the duration of study participation.
Women of childbearing potential and men must agree to use adequate contraception
Men and women of childbearing potential must be willing to use adequate contraception throughout the study and for  weeks after study drug discontinuation
Men and women of childbearing potential who do not practice contraception; women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation
Men (including men with vasectomies) must agree to use adequate contraception (a condom and another effective method of birth control) prior to registration, for the duration of study participation, and for at least  months thereafter; men must also agree not to donate sperm for the duration of study participation, and for at least  months thereafter
The subject must agree to use two effective forms of contraception beginning at least four () weeks prior to study entry, and continuing to do so for the duration of their participation in the study
TUMOR BIOPSY SEQUENCING: Women of childbearing potential and men must agree to use highly effective contraception prior to study entry, for the duration of study participation, and for  months after completion of study; breastfeeding should be discontinued while the patient is on this trial and for  days following last dose of study drug
Males & women of childbearing potential must agree to abstain from sex or use an adequate method of contraception for the duration of study, & for  months after last dose of study drug
Patients must agree to use  methods of adequate contraception for the duration of study participation, and for four months after discontinuing therapy
Agreement to use adequate contraception: women of child-bearing potential must use contraception prior to study entry and for six months after study participation; men that are sexually active whose partners are women of childbearing age must use condoms
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to enrollment; women of childbearing potential and men must agree to use adequate contraception prior to enrollment and for the duration of study participation
Men treated or enrolled on this protocol must agree to use  adequate methods of contraception starting with the screening visit, for the duration of study participation, and through  days after the last dose of MK- administration
Men, capable of fathering a child, who are unwilling to use adequate contraception prior to study entry, for the duration of study participation, and for at least  days after treatment has ended.
WOCBP and men must agree to use adequate contraception prior to study entry and for duration of treatment under this protocol; adequate contraception is defined as any medically recommended method (or combination of methods) per standard of care
Negative serum pregnancy test within  hours before starting study treatment in women with childbearing potential. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of the study participation
WOCBP and men must agree to use adequate contraception prior, to study entry, for the duration of study participation, and  weeks after the end of treatment
Women of childbearing potential and men must agree to use adequate contraception
Women of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study; both men and women must agree to use a barrier method of contraception for the duration of the study and until  weeks after the final dose of UC- (expected to be greater than  half-lives from pre-clinical data)
Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation
Men and women of childbearing potential must agree to use adequate contraception from the time of consent through  days after final study treatment.
Men treated or enrolled on this protocol must agree to use  adequate methods of contraception starting with the screening visit, for the duration of study participation, and through  days after the last dose of MK- administration
Patients should not become pregnant or breastfeed while on this study; sexually active patients must agree to use contraception prior to study entry, for the duration of study participation, and for  days after the last dose
Women of childbearing potential and men who participate in the study must agree to use adequate contraception (hormonal or barrier methods) before, during the study and for a period of  months after the last dose of chemotherapy
Women of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care
Women of childbearing potential and men must agree to use adequate contraception .
Women of childbearing potential and sexually active men must agree to use effective contraception prior to study entry, for the duration of study participation and for three months after completing treatment; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care
Women of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation and up to  months following completion of therapy; adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care
Women of child-bearing potential and sexually active men must agree to use adequate contraception prior to study entry for six months following duration of study participation
Female patients who are pregnant or breastfeeding. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
Pregnancy or nursing mothers; women of childbearing potential must have a negative pregnancy test and must agree to use adequate contraception prior to study entry and for the duration of study participation
Men of childbearing potential who agree to use contraception prior to study entry and for the duration of participation
Males & women of childbearing potential must agree to abstain from sex or use an adequate method of contraception for duration of study & for  months after last dose of study drug
. Men and women of childbearing potential must agree to use adequate contraception(double barrier birth control) for the duration of study therapy and for  months after the last dose of VS-.
Women of childbearing potential must agree to use two reliable methods of contraception from screening and up to  days after discontinuation of study treatment.
Pregnant women are excluded from this study; breastfeeding women should be excluded; women of childbearing potential and men must agree to use adequate contraception (barrier methods) before, during the study and for a period of  months after the last dose of the investigational agent
Women of childbearing potential and men should agree to use an effective form of contraception and to continue its use for the duration of study treatment and for a period of time after the last dose of study treatment
Women of childbearing potential and sexually active men must agree to use effective contraception prior to study entry, for the duration of study participation and for three months after completing treatment; adequate contraception is defined as any medically recommended method (or combination of methods) per standard of care
Women of childbearing potential must agree to use contraception as defined by protocol during treatment and for at least  months after completion of study treatment
Women of childbearing potential and men must agree to use adequate contraception
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to enrollment and must agree to use adequate contraception prior to enrollment and for the duration of study participation; subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least  days after the last dose of study drug
Women of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and for a period of  months. Female subjects considered not of childbearing potential must be documented as being surgically sterile or post-menopausal for at least  year.
Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation
Women with child-bearing potential who are not on hormonal contraception should be willing to use non-hormonal contraception (adequate barrier-type contraception or intrauterine device [IUD]) from the time the pregnancy test is performed for the duration of study participation, and  days after study drug cessation (for women of childbearing potential only)
Men must agree to use adequate contraception prior to study entry, for the duration of study participation and for at least  months thereafter
Women of childbearing potential must have a negative serum pregnancy test performed within  days prior to enrollment, must be non-lactating and must agree to use adequate contraception prior to enrollment and for the duration of study participation
Women of child-bearing potential must agree to use adequate contraception for the duration of study participation and for  months after completion of SL- and azacitidine administration; men treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation and  months after completion of SL- and azacitidine administration